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The farnesoid X receptor (FXR) signaling pathways have been established to be involved in the 
pathogenesis of hepatocellular carcinoma (HCC) in prior studies and one proposed mechanism 
may be through regulation of the ubiquitin specific peptidase 2 (USP2) gene. As the mechanism 
has yet to be defined, more research is needed to identify the role of FXR and USP2 in HCC 
development. This study investigated the effects of FXR signaling activation on the 
transcriptional expression of USP2 promoter and explored their potential role in the 
pathogenesis of HCC. The first objective was to investigate the expression of USP2 in human 
hepatocellular carcinoma cells (HepG2) by looking at the circadian endogenous USP2 
expression and then treating cells with FXR agonists and antagonists. The second objective 
was to characterize regulation of the USP2 promoter by transfecting cells with FXR and USP2 
promoter, followed by looking at the USP2 promoter activity. The effects of treatments with FXR 
agonists and FXR antagonists on USP2 promoter activities were then examined. Findings from 
this study will provide a better understanding of the potential mechanism into development of 
HCC and be the basis for future research. 
